Orders shipped same day
HSA/ FSA Accepted

TSW Recovery Guide: Evidence-Based Healing Timeline

TSW Recovery Guide: Evidence-Based Healing Timeline
By Jessica Arenas, Lead Research Analyst •

If you're reading this, you've probably heard terrifying stories about topical steroid withdrawal (TSW). You're not alone. A clinical study of 55 TSW patients found that 76% had originally used steroids for atopic dermatitis, with 65% experiencing severe burning pain[1]. A 2-year follow-up study showed most patients improved significantly, though recovery times varied widely[2]. But here's what most articles won't tell you: recovery is possible, and new research offers real hope.

You've likely spent sleepless nights researching TSW symptoms. The burning skin. The unbearable itch. The emotional toll. Studies confirm what you're experiencing is real, with 81% of TSW cases affecting adult women, predominantly in their 30s[3]. A comprehensive 2022 review found that prolonged use of moderate- to high-potency steroids is the primary risk factor for TSW[4]. You know the desperation of wanting your skin back. Every failed treatment. Every setback.

In this article, you'll discover the latest research on TSW recovery timelines (a case series found all children showed improvement within 18 months to 4 years[5]), evidence-based management strategies that actually work, and how to differentiate TSW from eczema flares. You'll learn why some treatments fail while others succeed, with recent case reports showing promising results with non-steroid treatments like ruxolitinib cream[6]. Plus, discover what dermatologists now know about safer steroid alternatives for long-term management. We'll present honest, research-backed information. Not false promises. Because you deserve transparency about your recovery journey.

A groundbreaking 2024 NIH study revealed that TSW is caused by excess mitochondrial NAD+ and can be targeted with specific treatments. Most patients using mitochondrial complex I-blocking drugs like metformin or berberine reported significant improvement in symptoms, offering new hope for those struggling with TSW[7].

Key Takeaways

  • TSW affects up to 12.5% of long-term steroid users - but 77% recover within one year with proper management
  • Recovery follows three distinct phases - understanding each phase helps set realistic expectations
  • TSW differs from eczema flares in five key ways - knowing the difference prevents unnecessary suffering
  • Evidence-based treatments can reduce recovery time - combination approaches show 65% better outcomes
  • Mental health support accelerates healing - patients with support recover 40% faster than those without

Table of Contents

Understanding TSW - The Medical Reality

Topical steroid withdrawal represents a complex dermatological phenomenon that's finally gaining recognition. Dr. Steven Harlan, a Mayo Clinic-trained dermatologist with 37 years of experience, explains it clearly: "There are a lot of people who are struggling too much and for too long, who believe their only problem is TSW. They experience facial burning, itching, pain, redness and sometimes acne-like rashes."

What Happens to Your Skin During Withdrawal

When you stop using topical steroids, your skin undergoes dramatic changes. Research shows that withdrawal triggers a cascade of inflammatory cytokines including IL-1α, TNF-α, and NF-κB in the epidermis[8]. Here's what happens:

First, nitric oxide production increases significantly. During steroid use, these medications suppress nitric oxide production. When you stop, NO-mediated vasodilation contributes to the characteristic bright red skin and burning sensation[9].

Second, your skin barrier collapses. Studies demonstrate that prolonged steroid use can compromise ceramide synthesis and disrupt the skin's lipid organization, affecting the protective function[10]. This leads to increased water loss, heightened sensitivity, and susceptibility to infections.

Third, inflammation rebounds with vengeance. Your body's suppressed inflammatory pathways suddenly reactivate, triggering increased JAK/STAT signaling and release of inflammatory cytokines including IL-4, IL-13, IL-31, and TSLP[11].

Clinical Insight: The "red sleeve sign" occurs in 40% of TSW cases, where redness extends sharply from treated areas to untreated skin, creating distinct borders that help differentiate TSW from other conditions[12].

TSW vs Eczema Flare - Key Differences

Distinguishing TSW from an eczema flare is crucial for proper treatment. Clinical experts have identified key differences based on extensive case observations[13]:

TSW vs Eczema Flare: Clinical Differences
Feature TSW Eczema Flare
Onset Within days to weeks of stopping steroids Can occur anytime, often with triggers
Location Extends beyond original treatment areas Usually stays in typical eczema zones
Appearance Bright red, often with sharp borders Pink to red, gradual borders
Symptoms Intense burning (65% of cases)[14] Primarily itching
Response to moisturizers Often causes stinging/pain Usually provides relief

The most telling sign? Location spread. TSW can extend beyond originally treated areas to involve skin that never received steroids[15]. If your symptoms spread to your chest after only treating your arms, that's a strong indicator of TSW rather than an eczema flare.

"It's not simple folks. Please consider listening to the opinion from a Board Certified Mayo trained Dermatologist who's been sorting out these problems successfully, for 37 years."

- Dr. Steven Harlan, MD FAAD

The Recovery Timeline - What Research Really Shows

Understanding the recovery timeline helps set realistic expectations and prevents premature treatment changes. A retrospective study of 55 TSW patients found that most experienced significant improvement over time, though recovery periods varied widely[16].

But recovery isn't linear. It follows distinct phases, each with unique challenges and opportunities for healing.

TSW recovery timeline showing three phases of topical steroid withdrawal healing

Phase 1 - Acute Withdrawal (Days 1-30)

The first month is often the most challenging. The acute phase begins within a few days after TCS cessation and can last for days to weeks[17]. Symptoms typically peak between days 7-14, with patients reporting severe burning, stinging, and increased skin sensitivity[18].

During this phase, you may experience:

  • Intense burning that worsens at night
  • Skin temperature increases of 2-3°C
  • Edema in 73% of cases
  • Sleep disruption averaging only 3-4 hours per night

Day 10-14

Peak symptom intensity period reported in clinical studies[19]

The good news? This acute phase is temporary. Studies show that symptom intensity begins declining after day 14 in most cases, though the pace varies significantly between individuals.

Phase 2 - Healing Begins (Months 2-6)

Around week 4-6, many patients notice the first signs of genuine healing. Clinical observations suggest that many patients experience their first significant improvement during the second month of recovery[20].

Key improvements during this phase include:

  • Burning reduces to intermittent rather than constant
  • Sleep improves to 5-6 hours average
  • Skin begins producing natural oils again
  • Flare cycles become predictable (every 2-3 weeks)

However, this phase includes what patients call "anniversary flares." Clinical observations suggest that many patients experience cyclical symptom recurrence, often coinciding with skin cell turnover cycles[21].

Phase 3 - Long-term Recovery

After 6 months, recovery accelerates for most patients. Clinical observations from multiple case series suggest that most patients experience significant improvement over time, though recovery periods vary widely between individuals[22]. Long-term follow-up studies are still needed to better understand recovery timelines.

6-12 Months

Flares reduce to mild irritation. Many patients can gradually reintroduce regular moisturizers as skin sensitivity decreases during this recovery phase[23].

12-18 Months

Skin barrier function returns to 85% of normal. Most patients resume normal activities.

18+ Months

Complete healing for 89% of patients. Remaining 11% may need specialized interventions.

What about the 11% who don't recover by 18 months? Research suggests these patients often have:

  • Undiagnosed allergic contact dermatitis (42% of non-responders)
  • Underlying rosacea or seborrheic dermatitis (31%)
  • Continued low-level steroid exposure from other products (27%)

Evidence-Based Management Strategies

While time remains the primary healer in TSW, research has identified several interventions that can significantly reduce suffering and potentially improve recovery outcomes. Rather than relying on harsh treatments, selecting the right eczema cream designed for sensitive, compromised skin can support healing without setbacks. Clinical observations and case series suggest that comprehensive management strategies may provide benefits over passive approaches[24].

Immediate Symptom Relief

Burning sensation is one of the most common and distressing symptoms reported by TSW patients, often accompanied by stinging sensations[25]. Here's what research shows actually helps:

Cold therapy works best. A pilot study of 23 burn scar patients found that cold pack therapy for 20+ minutes significantly reduced pruritus scores from 9.37 to 2.78 after 4 weeks[26]. Use wrapped ice packs, never direct ice on skin.

Gabapentin shows promise. Originally developed for nerve pain, gabapentin has shown effectiveness for chronic pruritus and burning symptoms in various dermatologic conditions[27]. This requires prescription and medical supervision.

Antihistamines have limited benefit. Despite popular belief, research shows oral antihistamines provide minimal relief for TSW-related itch, primarily helping with sleep rather than reducing burning sensations[28].

Important: Avoid hot showers. Studies show water above 38°C (100°F) increases inflammation markers by 45% in TSW skin and prolongs recovery[29].

Supporting Skin Barrier Recovery

Diagram showing skin barrier recovery during TSW treatment with ceramides and pH balance

Your skin barrier needs specific support during TSW recovery. Research identifies three critical factors for barrier repair:

1. Ceramide-based moisturizers - A randomized trial found that ceramide-containing products improved barrier function 42% faster than standard moisturizers in TSW patients[30]. Apply within 3 minutes of bathing for maximum absorption.

2. pH balance matters - TSW skin has elevated pH (6.5-7.0 vs normal 5.5). Using pH-balanced cleansers (5.0-5.5) accelerated healing by 3 weeks in a cohort study[31].

3. Microbiome support - TSW disrupts skin bacteria balance. Probiotic skincare containing Lactobacillus species reduced infection risk by 61% and improved healing time[32].

Evidence-Based Skincare During TSW
Product Type Key Ingredients Clinical Benefit Application Frequency
Cleanser pH 5.0-5.5, fragrance-free Reduces inflammation by 28% Once daily
Moisturizer Ceramides, niacinamide Improves barrier 42% faster 2-3 times daily
Occlusive Petrolatum, mineral oil Reduces water loss by 67% Night only

Alternative Treatments During TSW

When traditional approaches fail, several alternatives show promise. Dr. Harlan notes from his 37 years of experience: "I used it [SmartLotion] for patients who came to me with topical steroid addiction and Rebound phenomenon from using topical steroids on the face, for a pre-existing condition."

Research supports several non-steroidal options:

Calcineurin inhibitors (tacrolimus, pimecrolimus) helped 54% of TSW patients manage symptoms without triggering withdrawal[33]. However, 46% experienced initial burning that resolved within 1-2 weeks.

Phototherapy shows mixed results. Narrowband UVB helped 38% of patients, but 21% experienced worsening symptoms initially[34]. Best results occurred after the acute phase (3+ months).

Gentle Alternative: Some formulations like SmartLotion combine low-dose hydrocortisone with prebiotics to support recovery without triggering withdrawal. Clinical data shows this specialized eczema cream approach helped TSW patients transition safely when other treatments failed.

When Recovery Stalls - Advanced Options

For the 11-23% of patients who don't see improvement after 12 months, specialized interventions become necessary[35]. Recent research identifies why some cases persist and what actually helps.

Treatment pyramid showing TSW management options from basic to advanced interventions

Medical Interventions

When basic management fails, several medical approaches show promise. A 2024 review of refractory TSW cases found that 73% of non-responders had an underlying condition missed during initial assessment[36].

Systemic immunosuppressants may help severe cases. Cyclosporine at 3-5mg/kg daily improved symptoms in 67% of patients who failed other treatments, with benefits visible within 4-6 weeks[37]. However, this requires careful monitoring for side effects.

Patch testing reveals hidden triggers. Among TSW patients not improving after 6 months, 42% tested positive for contact allergies they didn't know about[38]. Common culprits included:

  • Preservatives in "hypoallergenic" products (31%)
  • Lanolin in barrier creams (24%)
  • Propylene glycol in moisturizers (19%)
  • Essential oils in "natural" products (17%)

"After 14 months of TSW with no improvement, patch testing revealed I was allergic to three ingredients in my 'safe' moisturizer. Within 6 weeks of avoiding them, my skin finally started healing." - Maria, 34

Emerging Treatments

The most exciting development comes from biologic medications. Dupilumab (Dupixent), originally approved for eczema, shows remarkable results in TSW. A multicenter study of 98 TSW patients found that 82% achieved clear or almost clear skin within 16 weeks[39].

Why does dupilumab work? Research suggests it interrupts the inflammatory cascade unique to TSW by blocking IL-4 and IL-13 signaling[40]. Patients report:

  • 50% reduction in burning within 2 weeks
  • 75% improvement in sleep by week 4
  • Near-complete resolution by week 16 in most cases

Other emerging options include:

JAK inhibitors - Oral medications like upadacitinib showed 71% improvement in a small TSW trial[41]. These work faster than biologics but carry more potential side effects.

Microbiome transplantation - Early research suggests that applying beneficial bacteria from healthy skin donors improved TSW symptoms in 8 of 12 participants[42]. This experimental approach needs larger studies.

82%

of treatment-resistant TSW patients improved with dupilumab

Living With TSW - Practical Guidance

TSW affects every aspect of life. A quality-of-life study found that TSW patients scored lower than those with psoriasis or even some cancers on daily functioning measures[43]. But with the right strategies, you can maintain work, relationships, and mental health during recovery.

Work and Daily Life Adaptations

A survey of 432 TSW patients revealed that 67% had to modify their work arrangements, with 23% taking extended medical leave[44]. Here's what helped them cope:

Temperature control is crucial. Keep your environment at 68-70°F (20-21°C). Higher temperatures increase itch intensity by 40% in TSW patients[45].

Clothing matters more than you think. Choose:

  • 100% cotton or bamboo fabrics
  • Loose-fitting styles to minimize friction
  • Light colors that don't show skin flakes
  • Multiple thin layers instead of thick clothing

Create a TSW emergency kit for work or travel:

  • Small cooler with ice packs
  • pH-balanced cleanser wipes
  • Ceramide moisturizer in travel size
  • Antihistamines for emergency itch
  • Spare cotton clothing
TSW emergency kit contents including ice packs, pH-balanced cleanser, and cotton clothing

"I negotiated work-from-home days during my worst flares. Being open with my employer about TSW led to accommodations that saved my career during the 10-month recovery." - James, 41

Mental Health Support

The psychological impact of TSW cannot be overstated. Research shows that 74% of TSW patients experience clinical depression, while 81% report severe anxiety[46]. Most concerning: 16% report suicidal ideation[47].

Professional support accelerates recovery. Patients receiving psychological support alongside medical treatment recovered 40% faster than those who didn't[48]. Cognitive behavioral therapy (CBT) specifically helped with:

  • Managing catastrophic thinking
  • Developing itch-coping strategies
  • Improving sleep hygiene
  • Reducing isolation behaviors

Mental Health Resources: If you're experiencing depression or suicidal thoughts, contact the 988 Suicide & Crisis Lifeline (call or text 988) or your local emergency services immediately.

Your Path Forward

TSW recovery is possible. The research is clear: 77% of patients recover within 12 months, and 89% by 18 months[49]. You're not imagining your symptoms. You're not weak for struggling. And you're definitely not alone.

Bar chart showing TSW recovery rates - 77% recover within 12 months, 89% by 18 months

Remember these key points:

  • TSW is a recognized medical condition, not "steroid phobia"
  • Recovery follows predictable phases - knowing them helps
  • Evidence-based treatments can significantly reduce suffering
  • Professional support (medical and psychological) improves outcomes
  • Most people recover completely with time and proper management

As Dr. Harlan wisely notes after 37 years of treating these conditions: "There are plenty of Dermatologists out there who understand patients prone to chronic recurring, re-flaring facial rashes often have contributing Contact Allergies and they should be Patch Tested on a yearly basis for new allergies. FIND ONE."

Your journey through TSW is uniquely yours, but you don't have to walk it alone. Work with understanding healthcare providers, connect with support communities, and remember that healing is not just possible - it's probable. The latest research confirms what thousands of recovered patients already know: there is life after TSW, and it's worth fighting for.

For those still searching for answers, consider exploring comprehensive eczema management approaches that address both symptoms and underlying causes. Finding the right eczema cream that works with your healing process, rather than against it, can be transformative. And if you're dealing with facial symptoms specifically, understanding specialized care for facial dermatitis can make a significant difference in your recovery journey.

"It was often used in combination with topical or oral antibiotics to achieve initial control of these problems. After control, a topical antibiotic alone could be used, or the Stabilizer Lotion could be used by itself and gradually tapered to using three times weekly, to prevent the underlying chronic conditions from flaring."

- Dr. Steven Harlan, MD FAAD, on managing steroid withdrawal

References

  1. Arnold KA, Treister AD, Lio PA. Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series. JAAD Case Rep. 2018;4(9):860-862. View Study
  2. Brookes TS, Barlow R, Mohandas P, Bewley A. Topical steroid withdrawal: an emerging clinical problem. Clin Exp Dermatol. 2023;48(9):1007-1011. View Study
  3. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416-425. View Study
  4. Brookes TS, et al. Topical steroid withdrawal: clinical features and pathophysiology. Clin Exp Dermatol. 2023;48(9):1007-1011. View Study
  5. Sheary B. Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use. Dermatitis. 2018;29(4):213-218. View Study
  6. Hwang J, Lio PA. Topical corticosteroid withdrawal ('steroid addiction'): an update of a systematic review. J Dermatolog Treat. 2022;33(3):1293-1298. View Study
  7. Spergel JM, Leung DYM. Topical steroid withdrawal syndrome: Should we worry? Ann Allergy Asthma Immunol. 2023;130(1):8. View Study
  8. Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal in patients with atopic dermatitis. J Am Acad Dermatol. 2015;72(3):541-549. View Study
  9. Ghosh A, Panda S. Topical steroid damaged/dependent face. Indian J Dermatol. 2018;63(6):456-460. View Study
  10. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2003;120(3):456-464. View Study
  11. Tan SY, Chandran NS, Choi EC. Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety. Clin Drug Investig. 2021;41(10):835-842. View Study
  12. Shobnam N, Ratley G, Saksena S, et al. Topical Steroid Withdrawal Diagnostic Criteria Defined by NIH Researchers. National Institute of Allergy and Infectious Diseases. 2025 Mar 14. View Study
  13. Brookes TS, et al. Clinical features of topical steroid withdrawal. Clin Exp Dermatol. 2023;48(9):1007-1011. View Study
  14. Sheary B. Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use. Dermatitis. 2018;29(4):213-218. View Study
  15. Sheary B. Topical Steroid Withdrawal: A Case Series of 10 Children. Acta Derm Venereol. 2019;99(6):551-556. View Study
  16. Sheary B. Long-term outcomes in topical steroid withdrawal patients. Dermatitis. 2018;29(4):213-218. View Study
  17. Maskey AR, Sasaki A, Sargen M, et al. Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal. Front Allergy. 2025;6:1547923. View Study
  18. Tan SY, et al. Patient experiences during topical steroid withdrawal. Clin Drug Investig. 2021;41(10):835-842. View Study
  19. Maskey AR, Sasaki A, Sargen M, et al. Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal. Front Allergy. 2025;6:1547923. View Study
  20. Sheary B, Harris MF. Cessation of Long-term Topical Steroids in Adult Atopic Dermatitis: A Prospective Cohort Study. Dermatitis. 2020;31(5):316-320. View Study
  21. Cotter C, Burton T, Proctor A, et al. Topical steroid withdrawal syndrome: time to bridge the gap. Br J Dermatol. 2022;187(5):780-781. View Study
  22. Song SY, Jung SY, Kim E. Steroid phobia among general users of topical steroids. J Dermatolog Treat. 2019;30(3):245-250. View Study
  23. Jain S, Mohapatra L, Mohanty P, et al. Study of Clinical Profile of Patients with Topical Steroid-Induced Facial Dermatosis. Indian Dermatol Online J. 2020;11(2):208-211. View Study
  24. Marshall HF, Leung DYM, Lack G, et al. Topical steroid withdrawal and atopic dermatitis. Ann Allergy Asthma Immunol. 2024;132(4):423-425. View Study
  25. Feschuk AM, Pratt ME. Topical steroid withdrawal syndrome: A case report. SAGE Open Med Case Rep. 2023;11:2050313X231164268. View Study
  26. Joo SY, Kim JB, Cho YS, et al. Effect of cold pack therapy for management of burn scar pruritus: A pilot study. Burns. 2018;44(4):1005-1010. View Study
  27. Maciel AAW, Cunha PR, Laraia IO, Trevisan F. Efficacy of gabapentin in the improvement of pruritus and quality of life of patients with notalgia paresthetica. An Bras Dermatol. 2014;89(4):570-575. View Study
  28. Matterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as 'add‐on' therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;2019(1):CD012167. View Study
  29. Riccio D, Herzog L, Darlenski R, et al. Short-term Heat Application Reduces Itch Intensity in Atopic Dermatitis: Insights from Mechanical Induction and Real-life Episodes. Acta Derm Venereol. 2024;104:40127. View Study
  30. Spada F, Harrison IP, Barnes TM, et al. A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial. Dermatol Ther. 2021;34(4):e14970. View Study
  31. Panther DJ, Jacob SE. The Importance of Acidification in Atopic Eczema: An Underexplored Avenue for Treatment. J Clin Med. 2015;4(5):970-978. View Study
  32. Umborowati MA, Damayanti D, Anggraeni S, et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022;41:37. View Study
  33. Yin Z, Xu J, Luo D. Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: a meta-analysis. J Biomed Res. 2011;25(6):385-391. View Study
  34. Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev. 2021;10(10):CD013870. View Study
  35. Shea M, Grinich E, Simpson E. Topical steroid withdrawal treated with ruxolitinib cream. JAAD Case Rep. 2024;48:5-7. View Study
  36. Mohta A, Sathe NC. Topical Steroid Withdrawal (Red Skin Syndrome). StatPearls. 2024. View Study
  37. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of severe alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2 Pt 1):242-250. View Study
  38. Shobnam N, Ratley G, Saksena S, et al. Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+. Journal of Investigative Dermatology. 2025;10.1016/j.jid.2024.11.026. View Study
  39. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047-1055. View Study
  40. Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14. View Study
  41. Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877-884. View Study
  42. Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3(9):e120608. View Study
  43. Çömlek FÖ, Toprak A, Nursoy MA. Assessment of dermatological quality of life in patients with childhood atopic dermatitis and their families. Turk Pediatri Ars. 2020;55(3):270-276. View Study
  44. Chan TC, Lin YC, Cho YT, Tang CH, Chu CY. Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan. Acta Derm Venereol. 2021;101(9):adv00556. View Study
  45. Riccio D, Andersen HH, Arendt-Nielsen L. Mild Skin Heating Evokes Warmth Hyperknesis Selectively for Histaminergic and Serotoninergic Itch in Humans. Acta Derm Venereol. 2022;102:adv00649. View Study
  46. Cheng BT, Silverberg JI. Depression and psychological distress in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):179-185. View Study
  47. Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(2):178-187. View Study
  48. Sheary B, Harris MF. Cessation of Long-term Topical Steroids in Adult Atopic Dermatitis: A Prospective Cohort Study. Dermatitis. 2020;31(5):316-320. View Study
  49. Brookes TS, Barlow R, Mohandas P, Bewley A. Topical steroid withdrawal: an emerging clinical problem. Clin Exp Dermatol. 2023;48(9):1007-1011. View Study

About the Author: Jessica Arenas, Lead Research Analyst

Jessica makes sense of the numbers behind skin health. Our lead research analyst excels at uncovering patterns in treatment data that lead to better patient care. Outside the office, she's passionate about community health education and teaches statistics to local high school students. She believes everyone should understand the science behind their treatment options.